Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Series C Preferred Stock
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Accumulated deficit
Series C Preferred Stock
Treasury stock
Non - controlling interests
Beginning balance (in shares) at Dec. 31, 2022     42,344,827            
Beginning balance at Dec. 31, 2022 $ (28,208)   $ 423 $ 122,633 $ 73 $ (171,757)   $ (16) $ 20,436
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Share-based compensation from issuance of options and compensation-based warrants 613     613          
Exercise of stock options (in shares)     5,200            
Exercise of stock options 5     5          
Accretion of 15.00% Series C preferred shares (8,879)     (8,879)          
Issuance of warrants 8,607     8,607          
Foreign currency translation adjustment 11       11        
Net income (loss) (24,643)         (24,643)      
Ending balance (in shares) at Mar. 31, 2023     42,350,027            
Ending balance at Mar. 31, 2023 (52,494)   $ 423 122,979 84 (196,400)   (16) 20,436
Beginning balance (in shares) at Dec. 31, 2022     42,344,827            
Beginning balance at Dec. 31, 2022 (28,208)   $ 423 122,633 73 (171,757)   (16) 20,436
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) (45,089)                
Ending balance (in shares) at Jun. 30, 2023     42,400,027            
Ending balance at Jun. 30, 2023 (74,195)   $ 424 121,748 59 (216,846)   (16) 20,436
Beginning balance (in shares) at Mar. 31, 2023     42,350,027            
Beginning balance at Mar. 31, 2023 (52,494)   $ 423 122,979 84 (196,400)   (16) 20,436
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Share-based compensation from issuance of options and compensation-based warrants 736     736          
Exercise of stock options (in shares)     50,000            
Exercise of stock options 5   $ 1 4          
Accretion of 15.00% Series C preferred shares (11,853)     (11,853)          
Issuance of warrants 9,882     9,882          
Foreign currency translation adjustment (25)       (25)        
Net income (loss) (20,446)         (20,446)      
Ending balance (in shares) at Jun. 30, 2023     42,400,027            
Ending balance at Jun. 30, 2023 (74,195)   $ 424 121,748 59 (216,846)   (16) 20,436
Beginning balance (in shares) at Dec. 31, 2023     49,999,345            
Beginning balance at Dec. 31, 2023 (129,184)   $ 500 111,982 (411) (261,691)   0 20,436
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Share-based compensation from issuance of options and compensation-based warrants 536     536          
Exercise of stock options (in shares)     182,888            
Exercise of stock options 2     2          
Accretion of 15.00% Series C preferred shares (13,781)     (13,781)          
Issuance of warrants 7,392     7,392          
Foreign currency translation adjustment (203)       (203)        
Net income (loss) (27,954)         (27,954)      
Ending balance (in shares) at Mar. 31, 2024     50,182,233            
Ending balance at Mar. 31, 2024 (163,192)   $ 500 106,131 (614) (289,645)   0 20,436
Beginning balance (in shares) at Dec. 31, 2023     49,999,345            
Beginning balance at Dec. 31, 2023 (129,184)   $ 500 111,982 (411) (261,691)   0 20,436
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) 106,401                
Ending balance (in shares) at Jun. 30, 2024     50,182,233            
Ending balance at Jun. 30, 2024 88,509   $ 500 102,880 (722) (19,618)   0 5,469
Beginning balance (in shares) at Mar. 31, 2024     50,182,233            
Beginning balance at Mar. 31, 2024 (163,192)   $ 500 106,131 (614) (289,645)   0 20,436
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Share-based compensation from issuance of options and compensation-based warrants 576     576          
Settlement of warrants (1,866)     (1,866)          
Settlement of warrants in subsidiary (3,023)     11,944         (14,967)
Series C preferred shares cancelled upon settlement   $ 130,542         $ 130,542    
Deemed contribution in connection with cancellation of preferred stock to Senior Lenders   $ 5,130         $ 5,130    
Accretion of 15.00% Series C preferred shares (14,318)     (14,318)          
Issuance of warrants 413     413          
Foreign currency translation adjustment (108)       (108)        
Net income (loss) 134,355         134,355      
Ending balance (in shares) at Jun. 30, 2024     50,182,233            
Ending balance at Jun. 30, 2024 $ 88,509   $ 500 $ 102,880 $ (722) $ (19,618)   $ 0 $ 5,469